Palvella Therapeutics, Inc. $PVLA Shares Sold by Montanova Capital LLC

Montanova Capital LLC lessened its stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,135,406 shares of the company's stock after selling 18,090 shares during the period. Palvella Therapeutics comprises about 2.9% of Montanova Capital LLC's investment portfolio, making the stock its 5th largest position. Montanova Capital LLC owned approximately 7.88% of Palvella Therapeutics worth $173,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in PVLA. Bank of America Corp DE increased its position in shares of Palvella Therapeutics by 25.4% in the 1st quarter. Bank of America Corp DE now owns 37,972 shares of the company's stock worth $4,733,000 after purchasing an additional 7,700 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Palvella Therapeutics by 688.9% during the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company's stock worth $2,232,000 after purchasing an additional 15,637 shares during the last quarter. Blue Owl Capital Holdings LP bought a new position in shares of Palvella Therapeutics during the second quarter worth about $5,541,000. Emerald Mutual Fund Advisers Trust acquired a new position in Palvella Therapeutics in the first quarter worth about $13,190,000. Finally, WCM Investment Management LLC acquired a new position in Palvella Therapeutics in the first quarter worth about $4,982,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer owned 2,154 shares in the company, valued at $327,860.34. The trade was a 66.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company's stock.

Palvella Therapeutics Stock Up 1.7%

PVLA opened at $152.59 on Tuesday. The company's 50-day moving average price is $146.69 and its 200 day moving average price is $127.75. Palvella Therapeutics, Inc. has a fifty-two week low of $49.81 and a fifty-two week high of $161.38. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -31.59 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). Research analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PVLA. Stephens restated an "overweight" rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th. Chardan Capital raised Palvella Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $209.14.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source